• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Melinda Magyari Discusses Data on Treating Pediatric MS

Video

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, discusses the current body of data on treating pediatric multiple sclerosis (MS).

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, discusses the current body of data on treating pediatric multiple sclerosis (MS).

Transcript

How good is our current body of data on treating pediatric MS?

Because there have not been randomized control trials, only a few of them in pediatric-onset MS, the current evidence is not very strong. Randomized controlled trials exclude patients younger than 18 years. So I would, and as you can see in my presentation, most of the patients have been treated with intramuscular interferons. So the body of evidence on that treatment is rather good. But we need more observational data. We need large cohorts, maybe to merge them. Because the data is there, we just have to provide evidence.

Related Videos
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Michael Morse, MD, Duke Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.